【摘要】 近年来，以胰高血糖素样肽-1受体激动剂和芬特明/托吡酯复方制剂为代表的减重药物，为青少年肥胖治疗带来了突破性进展,其通过靶向食欲调控中枢或神经递质再摄取抑制，显著改善青少年肥胖的临床结局。不仅能有效减轻体重，还能改善胰岛素抵抗、血脂异常等代谢问题。然而，其长期安全性、成本可及性及个体化用药策略仍需完善。未来需推进长期随访研究，建立真实世界数据库以支持个体化用药。药物治疗应协同生活方式干预，构建“家庭-医疗-社会”三位一体管理模式，实现青少年肥胖的精准防控。更多还原

【Abstract】 In recent years, weight-loss medications such as glucagon-like peptide-1 receptor agonist, and PHEN/TPM have brought breakthrough progress in the treatment of adolescent obesity. By targeting appetite control centers or inhibiting neurotransmitter re-uptake, they significantly improve clinical outcomes in obese adolescents. These drugs not only effectively reduce body weight but also ameliorate metabolic issues such as insulin resistance and dyslipidemia. However, their long-term safety, cost accessibility, and individualized medication strategies still require improvement. Moving forward, it is necessary to advance long-term followup studies and establish real-world databases to support personalized treatment. Medication therapy should be integrated with lifestyle interventions, building a “familymedical-society” tripartite management model to achieve precise prevention and management of adolescent obesity.更多还原